PDF(501 KB)
PDF(501 KB)
PDF(501 KB)
细胞药物的种类及生物学特性——细胞药物连载之一
The Types and Biological Characteristics of Cell Drug
细胞药物是以不同细胞为基础的用于疾病治疗的制剂、药物或产品的统称,是继放疗、化疗之后又一种临床有效的治疗手段,可实施个性化治疗。细胞药物的种类很多,按其生物学特性可分为传统体细胞、免疫细胞以及各种不同的干细胞等。经体外操作过的细胞群,如肝细胞、胰岛细胞、软骨细胞、树突状细胞、细胞因子诱导的杀伤细胞、淋巴因子激活的杀伤细胞、体外加工的骨髓或造血干细胞和体外处理的肿瘤细胞(瘤苗)等。细胞药物已在一些难治性疾病中得到应用,包括血液系统疾病、心血管系统疾病、消化系统疾病、神经系统疾病、免疫系统疾病和抗衰老等。细胞治疗涉及的细胞种类很多,且不同细胞或不同治疗方法各有特点。运用不同的细胞药物来修复病变细胞,以重建受损的功能细胞和组织,恢复其生物学功能,为细胞丢失或损伤性疾病的防治提供了崭新的思路。
Cell drug includes the agent, medicine or product that can be based on different cells to treat disease, which is an effective clinical therapeutical method after radiotherapy and chemotherapy and may be implemented individualized treatment. There are many types of cells drugs which are divided into the traditional somatic cells, immune cells and different types of stem cells, etc., according to their biological characteristics. The cells were operated outside the body including liver cells, islet cells, cartilage cells, dendritic cells, cytokine induced killer cells, lymphatic factor activated killer cells, processed bone marrow or blood stem cells in vitro, and treated tumor cells (tumor vaccines) in vitro, etc. Cell drug has already been used in some refractory diseases, including blood system diseases, cardiovascular system diseases, digestive system diseases, nervous system diseases, immune system diseases, and anti-aging. Cell therapy is involved in many cell types, and different cells or different treatment methods have different characteristics. Different cell drugs are used to repair the diseased cells for rebuilding the damaged function cells and tissues and restoring their biological function, which provides a new train of thought for the prevention and control of cell loss or traumatic disease.
细胞药物 / 细胞制剂 / 细胞产品 / 生物学特性 {{custom_keyword}} /
Cell product / Cell drug / Cell agent / Biological characteristics {{custom_keyword}} /
[1] Mount N M, Ward S J, Kefalas P, et al. Cell-based therapy technology classifications and translational challenges. Philos Trans R Soc Lond B Biol Sci,2015, 370(1680): 20150017.
[2] Garry G A, Garry D J. Somatic cell therapy for chronic heart failure: in search of mechanistic insights. J Card Fail, 2015,21(7):583-585.
[3] Kamigaki T, Ibe H, Okada S, et al. Improvement of impaired immunological status of patients with various types of advanced cancers by autologous immune cell therapy. Anticancer Res, 2015, 35(8):4535-4543.
[4] Fawaz F S, Hermiston T W, Dinter H. Allogeneic somatic cell therapy: process development challenges and future opportunities. Curr Opin Mol Ther,2010,12(4):383-385.
[5] Kamigaki T, Matsuda E, Okada S, et al. Prospective evaluation of safety of immune-cell therapy for patients with various types of advanced cancer. Anticancer Res,2014,34(8):4601-4607.
[6] Dunkin D, Mehandru S, Colombel J F. Immune cell therapy in IBD. Dig Dis, 2014,32(Suppl 1):61-66.
[7] Kim A, Shin D M, Choo M S. Stem cell therapy for interstitial cystitis/bladder pain syndrome. Curr Urol Rep,2016,17(1):1.
[8] Knoepfler P S. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Adv Drug Deliv Rev, 2015,82-83:192-196.
[9] Smith D C, Eisenberg P D, Manikhas G, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin Cancer Res, 2014,20(24):6295-6303.
[10] Gómez-Lechón M J, Lahoz A, Jiménez N, et al. Evaluation of drug-metabolizing and functional competence of human hepatocytes incubated under hypothermia in different media for clinical infusion. Cell Transplant,2008,17(8):887-897.
[11] Zheng Y W, Ohkohchi N, Taniguchi H. Quantitative evaluation of long-term liver repopulation and the reconstitution of bile ductules after hepatocellular transplantation. World J Gastroenterol,2005,11(39):6176-6181.
[12] van der Torren C R, Verrijn Stuart A A, Lee D, et al. Serum cytokines as biomarkers in islet cell transplantation for type 1 diabetes.PLoS One, 2016,11(1):e0146649.
[13] Ling Z, De Pauw P, Jacobs-Tulleneers-Thevissen D, et al. Plasma GAD65, a marker for early β-cell loss after intraportal islet cell transplantation in diabetic patients. J Clin Endocrinol Metab, 2015,100(6):2314-2321.
[14] Fotino N, Fotino C, Pileggi A. Re-engineering islet cell transplantation. Pharmacol Res,2015,98:76-85.
[15] Duif C, Koutah M A, Ackermann O, et al. Combination of autologous chondrocyte implantation (ACI) and osteochondral autograft transfer system (OATS) for surgical repair of larger cartilage defects of the knee joint. A review illustrated by a case report. Technol Health Care,2015,23(5):531-537.
[16] Yang L, Guo G, Niu X Y, et al. Dendritic cell-based immunotherapy treatment for glioblastoma multiforme. Biomed Res Int, 2015,2015:717530.
[17] Bregy A1, Wong T M, Shah A H, et al. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev,2013,39(8):891-907.
[18] Jkel C E, Vogt A, Gonzalez-Carmona M A, et al. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res,2014,2014:897214.
[19] Li Y, Meng F D, Tian X, et al. Impact of IL2 and IL2R SNPs on proliferation and tumorkilling activity of lymphokineactivated killer cells from healthy chinese blood donors. Asian Pac J Cancer Prev, 2014,15(18):79657970.
[20] Mackay-Sim A, Féron F. Clinical trials for the treatment of spinal cord injury: not so simple.Methods Mol Biol,2013,1059:229-237.
[21] Poglajen G, Vrtovec B.Stem cell therapy for chronic heart failure. Curr Opin Cardiol, 2015, 30(3):301-310.
[22] Kaji N, Baba Y. Nanobiodevice-based single biomolecule analysis, single-cell analysis, and in vivo imaging for cancer diagnosis, cancer theranostics, and iPS cell-based regenerative medicine. Anal Sci,2014,30(9):859-864.
[23] Freedman B S. Modeling kidney disease with iPS cells. Biomark Insights, 2015,10(Suppl 1):153-169.
/
| 〈 |
|
〉 |
